| Market Cap (cr): | ₹ 5784Cr. | Book Value: | ₹ 4 |
|---|---|---|---|
| Lot Size: | 1000 | 52 Week High: | ₹ 12 |
| 52 Week Low: | ₹ 4 | EPS: | -3.94 |
| Demat Account: | PB: | 2.2 | |
| Face Value: | 1 | Debt To Equity: | 1.58 |
| No Of Shares: | 642.67Cr. | Url: | https://pharmeasy.in/ |
Overview :
Key Takeaways
- API Holdings Limited is the Mumbai-headquartered parent of PharmEasy (India's e-pharmacy platform), Thyrocare Technologies (listed diagnostics), and Docon Technologies.
- FY25 revenue was ₹5,872 crore with cash burn remaining flat — the operational stabilisation story.
- The valuation reset is dramatic and must be understood: the ₹3,500 crore rights issue was priced at ₹5 per share, valuing the company at approximately $500 million — a ~90% drop from its $5.6 billion peak.
- ISIN INE0DJ201029 | Face Value ₹1 | EPS -1.05 | Book Value ₹2.15 | P/B 3.07 | Debt-to-Equity 0.621 | Minimum lot around 450 units.
- The DRHP filed on 9 November 2021 was withdrawn in August 2022, citing volatile market conditions and strategic considerations. No new DRHP has been confirmed.
- Company Overview & Fundamentals
API Holdings (PharmEasy) unlisted shares are among the most widely discussed — and most misunderstood — names in India's OTC market. This page gives you the complete picture including the parts most listings leave out: the 90% valuation collapse, the covenant breach, the structural loss-making, and equally the genuine turnaround work — EBITDA positivity, debt reduction, and asset monetisation.
Read the risk section carefully before investing.
Check today's API Holdings share price →
Call/WhatsApp: +91-8882245112 | contact@armssecurities.com
| Parameter | Details |
|---|---|
| Company Name | API Holdings Limited |
| Flagship Brands | PharmEasy, Thyrocare Technologies (listed), Docon Technologies |
| Headquarters | Mumbai, Maharashtra |
| Industry | Digital Healthcare — e-pharmacy, diagnostics, retail distribution |
| ISIN | INE0DJ201029 |
| Face Value | ₹1 per share |
| EPS | -1.05 (loss-making) |
| Book Value | ₹2.15 |
| P/B Ratio | 3.07 |
| Debt-to-Equity | 0.621 |
| Minimum Lot | ~450 units |
| Key Executive | Siddharth Shah — Executive Director & Vice Chairman |
| Independent Directors | Dr. Jaydeep Tank, Subramaniam Somasundaram |
Business Segments
1. PharmEasy — India's e-pharmacy and digital healthcare platform, competing with Tata 1mg, Netmeds, Flipkart Health+ and Amazon Pharmacy. Covers online medicine delivery, diagnostics booking, teleconsultation, and healthcare products.
2. Thyrocare Technologies (listed) — API Holdings acquired a 66.1% stake in 2021. Thyrocare operates a national chain of diagnostic and preventive care laboratories. In October 2025, PharmEasy sold a 10% stake in Thyrocare for ₹668 crore — an asset monetisation to strengthen the balance sheet.
3. Docon Technologies — clinic and doctor software.
4. Retail Distribution — pharmaceutical distribution and supply chain.
The Full Timeline — Rise, Collapse, Repair
| Period | Event |
|---|---|
| 2021 (June) | Acquires majority stake in Thyrocare (66.1%); valuation crosses $4 billion |
| 2021 | Raises ~$140 million via secondary sale — post-money valuation $5.6 billion |
| 9 Nov 2021 | DRHP filed with SEBI |
| FY21 | Net loss ₹641 crore |
| FY22 | Net loss balloons to ₹3,992 crore (RoC filings) |
| Aug 2022 | DRHP withdrawn — citing volatile market conditions and "strategic considerations" |
| 2023 | Loan covenant breach after failing to raise equity — putting assets including Thyrocare at risk of takeover by Goldman Sachs, which had lent ₹2,280 crore at 17–18% interest |
| May 2023 | Janus Henderson marks down valuation by half to $2.8 billion; Neuberger Berman cuts valuation 21% from $5.6bn to $4.4bn |
| April 2023 | Reports first-ever positive EBITDA (₹14 crore) on net revenue of ₹600 crore |
| Oct 2023 | ₹3,500 crore rights issue oversubscribed at ₹5 per share — valuation ~$500 million, a 90% drop from peak |
| H1 FY24 | Cumulative ₹60 crore EBITDA at API across April–September 2023 |
| Dec 2023 | Ranjan Pai invests ₹1,300 crore, becoming the largest shareholder. Prosus writes down PharmEasy holding by ~$118 million (owns ~13%) |
| Sept 2025 | API Holdings raises ₹1,700 crore via NCDs to repay debt |
| Oct 2025 | Sells 10% Thyrocare stake for ₹668 crore |
| FY25 | Revenue ₹5,872 crore; burn remains flat |
What Siddharth Shah Said About the Turnaround
Executive Director and Vice Chairman Siddharth Shah described the shift in mindset directly: not moving towards profitability or trying to be profitable — but simply being profitable. He noted the company clocked ₹60 crore of cumulative EBITDA across all six months of H1 FY24 (April–September 2023), attributing it to a common vision, teamwork, and out-executing.
Financial Performance — Multi-Year View
| Metric | FY21 | FY22 | FY23 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | ~₹6,644 Cr | ₹5,872 Cr |
| Total Expenses | — | — | ~₹8,065 Cr | — |
| Net Loss | ₹641 Cr | ₹3,992 Cr | Significant | Reduced |
| EBITDA | Negative | Negative | First positive month (Apr 2023, ~₹14 Cr) | Burn flat |
| Debt-to-Equity | — | — | — | 0.621 |
Reading These Numbers Honestly
1. The company is structurally loss-making — this is the central fact. Across all years, operating expenses have exceeded revenue. In FY23, revenue was approximately ₹6,644 crore against expenses of roughly ₹8,065 crore. That is sustained negative operating leverage — a fundamental weakness, not a temporary one.
2. But the trajectory has genuinely improved. FY22's ₹3,992 crore loss was catastrophic. By April 2023 the company reported its first positive EBITDA month, and H1 FY24 delivered ₹60 crore cumulative EBITDA. FY25 revenue of ₹5,872 crore with flat burn means losses are no longer expanding with scale — the most important improvement a cash-burning business can show.
3. Revenue has declined from peak. ₹6,644 crore (FY23) to ₹5,872 crore (FY25) reflects deliberate pruning of unprofitable business, consistent with the profitability-first strategy.
4. The debt story is being actively managed. The 2023 Goldman Sachs covenant breach was existential — Thyrocare itself was at risk. Since then: the ₹3,500 crore rights issue, Ranjan Pai's ₹1,300 crore, ₹1,700 crore of NCDs to repay debt, and the ₹668 crore Thyrocare stake sale. Debt-to-equity now sits at 0.621 — manageable.
5. Book value is ₹2.15 against a ₹1 face value, with P/B at 3.07. You are paying roughly three times book for a loss-making business — the entire investment case rests on future profitability, not current asset value.
6. Dependence on external capital is a stated weakness. The company has relied on rights issues and preference share allocations to fund operations and settle debt. Each round has diluted existing holders.
- Why Some Investors Buy API Holdings Unlisted Shares
- Valuation has already reset ~90% — from $5.6 billion to roughly $500 million at the rights issue. The froth is gone; today's entry is anchored far below peak.
- Genuine operational turnaround — from ₹3,992 crore FY22 loss to positive EBITDA and flat burn on ₹5,872 crore FY25 revenue.
- Thyrocare is a real, listed, monetisable asset — the ₹668 crore 10% stake sale demonstrated liquidity and provides a market-priced valuation anchor.
- Ranjan Pai's ₹1,300 crore at the reset valuation — a sophisticated healthcare investor (Manipal Group) becoming largest shareholder is meaningful validation.
- Structural sector tailwind — Indian e-pharmacy and digital diagnostics remain multi-decade growth markets.
- Debt is being systematically repaid — NCD refinancing and asset sales have reduced the crisis risk that existed in 2023.
- Scale is real — ₹5,872 crore revenue makes this one of India's largest digital healthcare platforms by revenue.
- Risks to Consider — Read This Before Anything Else
API Holdings is a high-risk investment. Do not size a position here as you would a profitable, dividend-paying company.
- Structurally loss-making. Operating expenses have exceeded revenue in every reported year. EPS is -1.05. There is no guarantee this reverses.
- Catastrophic value destruction has already occurred. From $5.6 billion to ~$500 million — a ~90% decline. Investors who bought at higher valuations lost most of their capital. This can happen again.
- Covenant breach history. In 2023 the company breached loan covenants after failing to raise equity, putting Thyrocare at risk of Goldman Sachs takeover on debt of ₹2,280 crore at 17–18% interest. That is a severe governance and liquidity warning from the recent past.
- Repeated dilution. Rights issues and preference allocations have repeatedly diluted existing shareholders. Further raises are plausible.
- DRHP was withdrawn. The November 2021 DRHP was pulled in August 2022. No confirmed new filing exists. There is no scheduled IPO.
- Institutional markdowns are documented — Janus Henderson halved its valuation to $2.8 billion; Neuberger Berman cut 21%; Prosus wrote down ~$118 million.
- Fierce competition from Tata 1mg, Netmeds (Reliance), Flipkart Health+ and Amazon Pharmacy — all backed by deeper-pocketed parents.
- Regulatory risk on e-pharmacy — India's online pharmacy regulations remain unsettled, with periodic court and government scrutiny.
- Selling the crown jewels reduces future value. Monetising Thyrocare stakes solves today's liquidity but removes tomorrow's earnings contribution.
- High exceptional expenses including impairment charges and redemption costs have repeatedly distorted reported results.
- How to Buy API Holdings Unlisted Shares from Arms Securities
- Get the live price — Call/WhatsApp +91-8882245112
- Confirm quantity — minimum lots around 450 units
- Share your CMR (Client Master Report) from your NSDL/CDSL DP
- Transfer payment — NEFT/RTGS/IMPS
- Receive shares in your demat within 24–48 hours (ISIN INE0DJ201029)
- FAQs — API Holdings (PharmEasy) Unlisted Shares
Arms Securities — India's trusted unlisted share specialist since 1990. We give you the honest picture, including risks, before you transact.
View all unlisted share prices → | Our procedure →
Q1. What is the current price of API Holdings (PharmEasy) unlisted shares?
Prices move daily with OTC demand and news flow. For today's confirmed Arms Securities quote and available quantity, call/WhatsApp +91-8882245112 or email contact@armssecurities.com.
Q2. Is PharmEasy profitable?
Not at the net level. API Holdings remains structurally loss-making — operating expenses have exceeded revenue in every reported year, and EPS stands at -1.05. However, the company reported its first positive EBITDA in April 2023 (~₹14 crore) and delivered ₹60 crore cumulative EBITDA in H1 FY24. FY25 revenue was ₹5,872 crore with burn remaining flat, meaning losses are no longer growing with scale.
Q3. Why did PharmEasy's valuation fall so sharply?
The company's valuation peaked at $5.6 billion in 2021. Mounting losses (₹3,992 crore in FY22), a 2023 loan covenant breach, and difficulty raising equity forced a ₹3,500 crore rights issue priced at ₹5 per share — valuing the company at approximately $500 million, a roughly 90% decline from peak. Institutional investors including Janus Henderson and Neuberger Berman marked down their holdings accordingly.
Q4. Will PharmEasy do an IPO?
API Holdings filed a DRHP on 9 November 2021 but withdrew it in August 2022, citing volatile market conditions and strategic considerations. No new DRHP has been confirmed. Investors should assume no scheduled listing and treat any IPO as speculative.
Q5. What is API Holdings' relationship with Thyrocare?
API Holdings acquired a 66.1% stake in Thyrocare Technologies in 2021. Thyrocare is a listed diagnostics chain, making it a market-valued, monetisable asset. In October 2025, PharmEasy sold a 10% Thyrocare stake for ₹668 crore to strengthen its balance sheet.
Q6. Who are PharmEasy's largest shareholders?
Ranjan Pai became the largest shareholder after investing ₹1,300 crore in December 2023. Prosus Ventures owns approximately 13%. Other investors have included Temasek, with total funding across the company's history at approximately $1.6 billion. Siddharth Shah serves as Executive Director and Vice Chairman.
Q7. Is API Holdings' debt under control?
It has improved substantially. Following the 2023 covenant breach on Goldman Sachs debt of ₹2,280 crore at 17–18% interest, the company completed a ₹3,500 crore rights issue, received Ranjan Pai's ₹1,300 crore, raised ₹1,700 crore via NCDs in September 2025 specifically to repay debt, and sold a 10% Thyrocare stake for ₹668 crore. Debt-to-equity now stands at approximately 0.621 — manageable, though the company remains dependent on external capital.
Also Read: OYO (Oravel Stays) Unlisted Shares | Lakeshore Hospital Unlisted Shares | Tax on Unlisted Shares
+91-8882245112 | contact@armssecurities.com | www.armssecurities.com
Balance Sheet of Pharmeasy Unlisted Shares
| category | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Equity | 3110.33 | 2257.92 | 1638.54 | 6246.52 | 4023.75 | 309.35 |
| Liabilities | 2426.37 | 4052.25 | 3851.02 | 474.99 | 118.63 | 322.44 |
| Total Equity and Liabilities | 5536.70 | 6310.18 | 5489.56 | 6721.51 | 4142.38 | 631.79 |
| Net Fixed Assets | 23.13 | 14.48 | 35.87 | 331.23 | 1.20 | 56.71 |
| Capital Work-in-progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 |
| Other Non current Assets | 4656.84 | 4459.80 | 4790.67 | 6188.89 | 2405.65 | 38.60 |
| Current Assets | 856.73 | 1835.90 | 663.02 | 201.39 | 1735.54 | 536.13 |
| Total Assets | 5536.70 | 6310.18 | 5489.56 | 6721.51 | 4142.38 | 631.79 |
Profit and Loss of Pharmeasy Unlisted Shares
| category | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Net Revenue | 549.70 | 513.75 | 668.64 | 169.74 | 38.23 | 28.45 |
| Total Operating Cost | 1049.61 | 936.82 | 1551.62 | 1036.52 | 120.58 | 9.16 |
| Operating Profit (EBITDA) | -499.91 | -423.07 | -882.98 | -866.78 | -82.36 | 19.29 |
| Other Income | 283.72 | 545.48 | 565.56 | 177.10 | 24.15 | 0.15 |
| Depreciation and Amortization Expense | 5.76 | 10.70 | 14.30 | 3.52 | 0.23 | 0.13 |
| Profit Before Interest and Taxes | -221.95 | 111.71 | -331.72 | -693.20 | -58.43 | 19.31 |
| Finance Costs | 382.89 | 541.81 | 439.73 | 46.86 | 2.97 | 0.15 |
| Profit Before Tax and Exceptional Items Before Tax | -604.84 | -430.10 | -771.45 | -740.06 | -61.40 | 19.16 |
| Exceptional Items Before Tax | 829.83 | -1726.96 | 4467.70 | 4340.96 | 0.00 | 0.00 |
| Profit Before Tax | -1434.67 | -2157.06 | -5239.15 | -5081.02 | -61.40 | 19.16 |
| Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.02 |
| Profit for the Period from Continuing Operations | -1434.67 | -2157.06 | -5239.15 | -5081.02 | -61.48 | 19.14 |
| Profit from Discontinuing Operations After Tax | -0.19 | 0.00 | -85.36 | 0.00 | -166.36 | -317.88 |
| Profit for the Period | -1434.86 | -2157.06 | -5324.51 | -5081.02 | -227.84 | -298.74 |
Net Sales (in cr.)
Total Income (in cr.)
Operating Profit (in cr.)
Net Profit (in cr.)
Shareholder Funds (in cr.)
Total Assets (in cr.)
Frequently Ask Question